anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, medicinal preparations. SUBSTANCE: amniotic fluid is taken in women at delivery, centrifuged, supernatant is frozen and then thawed out. Suspension is subjected for low-speed centrifugation, precipitate is resuspended in distilled water and extracted with organic solvents. Extract is treated with aqueous-salt solutions and organic solvents were removed. Residue is emulsified with sterile distilled water and lyophilized. EFFECT: simplified method, high quality of the end product. 1 tbl
Patients receive CMV-DC vaccine intradermally and administered in equal portions to each inguinal region. Vaccination repeats every 1-3 weeks for up to 3 doses in the absence of unacceptable toxicity.
Microcapsules for protecting probiotics and methods of making same are provided. In some embodiments, the microcapsules are used to provide delivery of probiotics, combinations of probiotics and prebiotics, and/or synbiotics through the stomach of a mammalian subject to its lower gastrointestinal tract. In some embodiments, the microcapsules comprise a biopolymer and a plant-based protein. In some embodiments, the microcapsules include alginate, iota- carrageenan or deacylated gellan gum as the biopolymer. In some embodiments, the microcapsules include chickpea protein, pea protein or soy protein as the plant-based protein. An emulsion containing the biopolymer, the plant-based protein, and the probiotic material to be encapsulated can be subject to crosslinking to form the microcapsule.
Combination treatment DFF332 + Spartalizumab + Taminadenant. This arm will not open.
FIELD: medicine. SUBSTANCE: method involves administering thiazofurine first in high doses to stimulate sharp drop in inosine monophosphate dehydrogenase activity. The so obtained results are supported by continuously introducing thiazofurine in lower doses to reach stabilization of hematological values and stable remission state. Next to it, ribavirine is administered in continuously lowering doses until the minimum dose is achieved that holds at least one of the values so that inosine monophosphate dehydrogenase activity is less than 10%, guanosine triphosphate concentration is less than 20% and blast cells quantity in the bone marrow is less than 5%. EFFECT: prolonged remission period. 24 cl, 5 dwg
Participants will receive meals that adhere to their specified nutritional targets dependent upon their cirrhosis complication of hepatic encephalopathy (HE) and/or ascites. Participants with HE will receive high-protein (approximately 1 gram of medication per kilogram of the body weight (1g/kg/day) and high-calorie (approximately 30c/kg/day) meals. Participants with HE and ascites will receive high-protein and high-calorie meals that are also low-sodium (less than or equal to 2000 milligrams a day).
PURPOSE: A process for preparing as cosmetic material as a hybrid matter comprising a cosmetic active component and layered metal hydroxide is provided. The hybrid matter has excellent stability, low toxicity, low irritation, sustained release property and dispersibility, therefore, the cosmetic containing the same has also characteristics such as skin whitening, comedolytic activity, wrinkle resistance, brown spot removal, skin moisturizing, harmful UV shielding, waste matter removal, etc. CONSTITUTION: The hybrid matter comprises: a cosmetic active component selected from vitamin A, vitamin C, vitamin E, vitamin derivatives, lactic acid, citric acid, kojic acid, indole-3-acetic acid and salicylic acid; and a layered metal hydroxide as a metal double-layered hydroxide. The layered metal hydroxide as starting material, reacts in a basic solution to produce a layered metal hydroxide salt. The layered metal hydroxide salt is dispersed in a water solvent or a mixed solvent, mixed with a cosmetic active component and then reacts. The surface of the hybrid matter is coated with at least one selected from the group consisting of polyvinyl alcohol, polyethylene glycol, cellulose, polymethylmethacrylate and silane.
Each prefilled ATNAA is a single-dose autoinjector that provides an intramuscular dose of atropine, a cholinergic muscarinic antagonist, and pralidoxime chloride, a cholinesterase reactivator, in a self-contained unit, specifically designed for automatic self- or buddy-administration by military personnel.

When activated, each ATNAA injection delivers the following:

  * 2.1 mg of atropine in 0.7 mL of sterile, pyrogen-free solution containing 12.47 mg glycerin, not more than 2.8 mg phenol, 3.05 mg sodium citrate dihydrate, 3.5 mg citric acid monohydrate, and Water for Injection. The pH range is 4.0 – 5.0.
  * 600 mg of pralidoxime chloride equivalent to 476.6 mg of pralidoxime in 2 mL of sterile, pyrogen-free solution containing 40 mg benzyl alcohol, 22.5 mg glycine, and Water for Injection. The pH is adjusted with hydrochloric acid. The pH range is 2.0 – 3.0.



After ATNAA has been activated, the empty autoinjector should be disposed of properly [see Dosage and Administration (2.2)]. It cannot be refilled, nor can the protruding needle be retracted.

Atropine occurs as white crystals, usually needle-like, or as a white, crystalline powder. It is slightly soluble in water with a molecular weight of 289.38. Atropine, a naturally occurring belladonna alkaloid, is a racemic mixture of equal parts of d- and l-hyoscyamine, with activity due almost entirely to the levo isomer of the drug.

Chemically, atropine is designated as 1αH,5αH-Tropan-3α-ol (±)-tropate. Its empirical formula is C17H23NO3 and its structural formula is as follows:

Pralidoxime chloride is an odorless, white to pale-yellow crystalline powder, freely soluble in water, with a molecular weight of 172.61. Chemically, pralidoxime chloride is designated as 2-formyl-1-methylpyridinium chloride oxime. Its empirical formula is C7H9CIN2O and its structural formula is indicated above.
The present invention relates to the use of cannabidivarin (CBDV) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). In a further embodiment the invention relates to the use of CBDV in the treatment of schizophrenia. CBDV has been shown to be particularly effective in improving cognitive dysfunction in rodent models of ASD, FXS, RS, AS and schizophrenia. The CBDV is preferably substantially pure. It may take the form of a highly purified extract of cannabis such that the CBDV is present at greater than 95% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBDV is synthetically produced.
One day before the operation, the participants in the experimental group were given breathing exercise training, and they were applied 5 times a day for 10 repetitions until the 30th day after the operation. Introductory Information Form, State-Trait Anxiety Scale, Visual Comparative Sleep Scale and Recovery Quality-40 Questionnaire were used to collect data 1 day before surgery, on the day of surgery, on the 1st day, 15th and 30th days after surgery.
BACKGROUND: Older people in low- and middle-income countries are more susceptible to the impact of childhood experiences. This study comprehensively examines how childhood socioeconomic status (SES) and adult SES collectively influence late-life healthy longevity from a life course perspective, providing insights for shaping health-related policies.
METHODS: This study analyzed data from the Chinese Longitudinal Healthy Longevity Survey (1998-2018) with 37,264 individuals aged 65 and above. Using R software, we applied continuous-time multi-state models incorporating the Rockwood frailty index with 38 indicators to assess participants' health. Childhood SES or life course SES trajectories were core explanatory variables, while age and gender were controlled. Multinomial regression estimated annual transition probabilities between different states, and the multi-state life table method calculated total and frailty-specific life expectancy (LE).
RESULTS: (1) Social mobility among older people in China showed an upward trend from childhood to adulthood. (2) Transition probabilities for robust-frailty, robust-dead, and frailty-dead increased with age, while frailty-robust decreased. Transition probabilities and LE varied across different childhood SES (low, medium, high) or life-course SES trajectory categories (low-low, low-medium, low-high, medium-low, medium-medium, medium-high, high-low, high-medium, high-high), with probabilities of robust-frailty, robust-dead, and frailty-dead decreasing sequentially across different categories, and frailty-robust increasing sequentially across different categories. Total LE, robust LE, and robust LE proportion increased sequentially across different categories, while frailty LE decreased sequentially across different categories. (3) Women had higher total LE and frailty incidence, but lower recovery rate, mortality risk, robust LE, and robust LE proportion compared to men.
CONCLUSION: Favorable childhood SES and lifelong accumulation of SES advantages protect against frailty morbidity, improve recovery rate, reduce mortality risk, and increase total LE, robust LE, and robust LE proportion. High childhood SES has a stronger protective effect than high adult SES, indicating the lasting impact of childhood conditions on healthy longevity. Systematic interventions in education, food supply, and medical accessibility for children from impoverished families are crucial.
Participants will have extended Emergency Department visit by having an observation (which could be up to 23 hours) time in addition to the standard ED visit. In addition, information will be gathered about about the participants, use of opioids, healthcare visits, the quality of health, life, and treatment, and other topics. Urine or saliva or both may also be collected.
Participants allocated to the swimming programme will be invited to complete three short questionnaires to assess general health, back pain, and swimming ability and experience, see Appendix H, I and J. Both the swimming and physiotherapy groups will complete the three outcome measures, the Oswestry low back pain disability index (ODI), the pain self-efficacy questionnaire (PSEQ), and the EQ-5D-3L, before the intervention, after the last appointment and 6 months later. Data will be collected to report participant characteristics: including age, gender, and length of time with LBP. A follow up participant feedback questionnaire will be distributed to the participants in the swimming arm on completion of the programme and 6 months later.
Neck pain leads to a decreased range of motion in the cervical spine, bringing along functional losses. As a result, this situation is associated with many disabilities. Evaluation of neck joint motion is essential in patients with chronic neck pain. It is used to evaluate the neck pain level and functional deficit level of the patient. In this way, it is possible to evaluate the effectiveness of the treatment applied to the patient during the rehabilitation process. Generally, this evaluation can be made and interpreted by an experienced clinician. However, patient perception provides a better understanding of patients' needs and problems by converting clinical data into a patient-centered measure. Moreover, the patient's perspective can add valuable information to the examination by creating a holistic picture of the patient's problems, possible needs, and expectations. In 2018, the "Self Administered Neck Mobility Assessment Tool (S-ROM-Neck)" survey was developed by Langenfeld et al. With this questionnaire, developers purposed to evaluate the neck joint motion perception of the patients, subjectively. There is no Turkish version of the questionnaire. The aim of our study is to develop the Turkish version of the S-ROM-Neck questionnaire, to analyze its cultural adaptation, and to reveal its validity and reliability.
ABSTRACT OF THE DISCLOSURE     A novel human cancer associated protein, termed Cl 1AC, having Cl inactivator-like function has been provided.  Diag-nostic tests based on demonstrating the presence of Cl 1AC have also been provided.  In addition, antibodies and anti-sera with specificity against Cl 1AC have been discovered. Matrix-immobilized antibodies have also been discovered.  The Cl 1AC is preferably prepared by immunizing a non-human animal against an .alpha.-neuramino glycoprotein having inhibitory activity upon Cl esterase hydrolyizing effect, and inhibitory effect on Cl activation of C4 as shown by the inhibition of complement haemolysis, which process comprises:  immunizing a non-human animal against the said .alpha.-neuramino glycoprotein; and then harvesting serum from the immunized animal.  The invention also provides a therapy of human cancer using antisera or anitbodies with specificity against Cl 1AC:  A novel human cancer associated protein; termed CAAC, and antisera and anti-bodies with specificity against CAAC have also been discovered. The used of rabbit antihuman C4 is also provided for monitoring cancer diseases.
Disclosed herein are a process or method for the preparation of prasugrel and several novel crystalline forms of prasugrel hydrochloride. The process comprises preparation of prasugrel by acetylation in solvents which have low boiling point and/or low toxicity, and the process not only avoids using solvents which have high boiling point and/or high toxicity such as toluene, acetonitrile and so on, but also resolves the problem about thermal instability of prasugrel, and the loss of prasugrel is reduced, as well as the yield is raised. The yield of prasugrel is higher than 85% and the purity is higher than 99.5%. The process can prepare prasugrel and its pharmaceutically acceptable salts. The novel crystalline forms of prasugrel hydrochloride are crystalline form H1, H2 and H3, and their performance in oral absorbability, activating metabolism and inhibiting platelet aggregation is excellent. They have a low toxicity and good thermal stability, and are applicable to the preparation of a drug for preventing or treating diseases caused by thrombosis or embolism.
People living with HIV who are at least 35 years of age and who have one or more of the following conditions: hypertension, dyslipidemia, or type 2 diabetes. All genders, races and ethnicities will be included in this study. Subjects will have a telephone visit and be electronically consented to study and complete an electronic survey.
Occlusal Splint (OS) + Pain Neuroscience Education (PNE) + Motor Imagery (MI) + Action Observation (AO) + Jaw and Neck Exercises (JNE) All participants in this arm will receive OS (they must use every night during the study) and will receive physiotherapy treatment including PNE, MI, AO and JNE, in 2 sessions per week, each lasting 60 minutes, during 5 weeks. For PNE a power-point presentation with metaphors, images and videos will be employed. For the MI, the participants will be asked to judge the laterality of different cervical images presented on the screen of a cell phone. The laterality task will be executed using an application called Recognize Neck, developed by the NOI group. The AO will be carried out using videos of mandibular and cervical exercises. The JNE program will be performed 3 sets of 10 repetitions. The exercises will be executed with a total time per session of 20 minutes, initially at the clinic and later at home.
Tooth/teeth are extracted with minimally invasive approach using piezo surgery and when necessary sectioning after local anesthesia (Articaine 40 mg/mL with epinephrine 10 μg/mL; or Lidocaine 20mg/ml with 10 ug/ml). Extraction sockets are thoroughly degranulated to remove all remnants of soft tissue and residual restorations or material which may have extended beyond the tooth apex. After copious irrigation, the socket condition is recorded, which includes, thickness and location of buccal/facial crestal alveolar bone.
MATERIALS AND METHODS FOR TREATING AND MANAGING ANGIOGENESIS-MEDIATED DISEASESAbstract Disclosed herein are materials and methods suitable for treating sites of pathological angiogenesis and abnormal neovascularization. Sites ofpathological angiogenesis or abnormal neovascularization can be treated bycontacting a surface at or adjacent or in the vicinity of an area of pathological angiogenesis or abnormal neovascularization with an implantable material. Theimplantable material comprises a biocompatible matrix and cells and is in an amount effective to treat the affected site. The composition can be a flexibleplanar material or a flowable composition. Diseases susceptible to treatment withthe present invention include, for example, macular degeneration, rheumatoid arthritis, psoriasis, psoriatic arthritis, systemic inflammatory diseases, andtreatment of tumors by surgical resection, radiation therapy or chemotherapy. (No suitable figure)
At enrollment, participants will be told to expect 2 SMS reminders for measles vaccine; first, at 3 days before and second, on the day before the scheduled measles vaccine at 9 months of age. At most, enrolled caregivers will receive three text messages (two for the measles vaccine and one for welcoming mother to the study). Text messages will be sent in English, Kiswahili or Dholuo language, according to the mother's preference. These reminders will have information about the child's scheduled immunization date.
Participants will attend weight loss groups weekly for 8 weeks, then biweekly for 16 weeks, then monthly between months 6 and 12. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet.
The utility model discloses a medicinal moxibustion paste, which relates to a medicine paste used for the treatment of a plurality of disease. The utility model is composed of a medical tape to which the anti-hypersusceptibility disposal is carried out, a leak-proof film, a leak-proof ring, and a medical sopping cushion. The leak-proof film is stuck at the middle of the medical tape, the leak-proof ring is stuck on the leak-proof film, and the medical sopping cushion is stuck inside the leak-proof ring. Fill the liquor into the bottle for standby, and when in use, drip a certain amount of the liquor on the medical sopping cushion of the utility model, and then adhibit to the pain part or the required point. The utility model has the advantages of novel designing and convenient usage. The liquor is not dripped onto the medical sopping cushion until use, and the availability of the medicine action is high, the contact area is small and the pertinence of the treatment is great. Adhibiting the medicinal moxibustion paste to different points, the broil treatment effect can be carried out to treat different diseases.
A system (100) comprises one or more processors (110) and one or more storage devices (120). The system (100) is configured to receive first patient-related image data of an image taken from a patient and identify a first anatomic feature in the first patient-related image data. Further, the system (100) is configured to generate merged patient-related image data based on the first patient-related image data and second patient-related image data of the patient. The second patient-related image data includes a representation of the same anatomic feature as the first anatomic feature identified in the first patient-related image data. Further, the first patient-related image data was received from a first source and at least a part of the second patient-related image data was received from a different, second source, the first patient-related image data was generated by a first imaging technology and at least a part of the second patient-related image data was generated by a different, second imaging technology, and/or the first patient-related image data was taken from the patient at a first point in time and at least a part of the second patient-related image data was taken from the patient at a second point in time. The first point in time differs from the second point in time at least by one month.
Prednisolone Sodium Phosphate was not formally evaluated in carcinogenicity studies. Review of the published literature identified the potential for malignancy at doses within the therapeutic range. In a 2-year study, male Sprague-Dawley rats administered prednisolone in drinking water at an estimated continuous daily prednisolone consumption of 368 mcg/kg/day (equivalent to 3.5 mg/day in a 60 kg individual based on an mg/m2 body surface area comparison) developed increased incidences of hepatic adenomas. However infrequent administration of prednisolone did not result in malignancy. In an 18-month study, intermittent (1, 2, 4.5 or 9 times per month) oral gavage of 3 mg/kg prednisolone did not induce tumors in female Sprague-Dawley rats (equivalent to 29 mg in a 60 kg individual based on a mg/m2 body surface area comparison).

Prednisolone Sodium Phosphate was not formally evaluated for genotoxicity. However, in published studies prednisolone was not mutagenic with or without metabolic activation in the Ames bacterial reverse mutation assay using Salmonella typhimurium and Escherichia coli, or in a mammalian cell gene mutation assay using mouse lymphoma L5178Y cells, according to current evaluation standards. In a published chromosomal aberration study in Chinese Hamster Lung (CHL) cells, a slight increase was seen in the incidence of structural chromosomal aberrations with metabolic activation at the highest concentration tested, however, the effect appears to be equivocal.

Prednisolone Sodium Phosphate was not formally evaluated in fertility studies. However, alterations in motility and numbers of spermatozoa, and menstrual irregularities have been described with clinical use [see Adverse Reactions (6)].
AIM: Chemosensory anhedonia refers to the lack of hedonic ability to experience pleasure through the senses of smell and taste, which reduces the pleasure and comfort of food, and increases the risk of nutritional and immune deficiencies. However, there is no direct scientific evidence regarding chemosensory anhedonia in patients with late-life depression (LLD). The aim of this study was to investigate chemosensory anhedonia in patients with LLD, and its potential association with depressive symptoms and cognitive function.
METHODS: A total of 114 patients with LLD and 92 normal controls were included in this study. They experienced clinical assessment, Chemosensory Pleasure Scale assessment, 17-item Hamilton Depression Rating Scale assessment and cognitive assessments, which contain the Verbal Fluency Test. The associations between chemosensory pleasure and depressive symptoms or cognitive function in patients with LLD were explored using partial correlation analysis and mediation analysis.
RESULTS: The Chemosensory Pleasure Scale scores were lower in the LLD group than in the normal control group, and were negatively correlated with the total scores and factors' scores (retardation, cognitive bias and anxiety/somatization) of the 17-item Hamilton Depression Rating Scale, and positively correlated with the Verbal Fluency Test scores. The scores for the Food and Imagination dimensions of the Chemosensory Pleasure Scale showed partial mediating effects on the differences in Cognitive bias (a factor of the 17-item Hamilton Depression Rating Scale) between patients with LLD and normal controls.
CONCLUSIONS: Patients with LLD showed significant chemosensory anhedonia, and both depressive symptoms and cognitive impairment were associated with the severity of chemosensory anhedonia. Enhancing chemosensory pleasure in patients with LLD could potentially ameliorate their depressive symptoms. Geriatr Gerontol Int 2024; 24: 1022-1029.